deltatrials
Completed PHASE3 NCT00172055

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Sponsor: Novartis Pharmaceuticals

Conditions Cancer Prostate
Interventions Zoledronic acid
Updated 7 times since 2017 Last updated: Mar 2, 2017 Started: Dec 31, 2004 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

Listed as NCT00172055, this PHASE3 trial focuses on Cancer Prostate and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Mar 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Mar 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderlecht, Belgium, Antwerp, Belgium, Bruges, Belgium, Brussels, Belgium, Charleroi, Belgium, Edegem, Belgium, Ghent, Belgium, Gosselies, Belgium, Kortrijk, Belgium, Leper, Belgium and 9 more location s